KN-002 is under clinical development by Kinaset Therapeutics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect KN-002’s likelihood of approval (LoA) and phase transition for Asthma took place on 06 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their KN-002 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
KN-002(formerly known as VR-588) is under development for the treatment of severe inflammatory airway diseases including asthma, chronic obstructive pulmonary disease (COPD) and other unspecified disease. It is a small molecule administered by inhalation. The drug candidate is a selective pan-JAK inhibitor. It act by targeting JAK1, JAK2, JAK3 and tyrosine kinase 2
Kinaset Therapeutics overview
Kinaset Therapeutics is a biopharma company developing novel respiratory therapeutics. It is headquartered in Medfield, Massachusetts, the US.
Quick View KN-002 LOA Data
|Highest Development Stage|